GO:0070371 ERK1 and ERK2 cascade: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070371 (ERK1 and ERK2 cascade) is a biological process MAPK cascade that starts with MAP3K activation, proceeds through MAP2K, and culminates in ERK1 (MAPK3) or ERK2 (MAPK1) activation.
• The cascade is activated by mitogens, growth factors, G protein-coupled receptors, and drives cell proliferation, differentiation, and development.
• ERK1 and ERK2 are structurally related but non-redundant in some contexts, with distinct knockout phenotypes and substrate preferences.
• Dysregulated ERK1/2 signaling is a hallmark of many cancers, and inhibitors targeting MEK and ERK are in clinical development.
• The cascade is regulated by scaffold proteins, phosphatases (DUSPs), and feedback phosphorylation of upstream components.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect ERK1/2-specific functions and therapeutic vulnerabilities.
Description
The ERK1 and ERK2 cascade (GO:0070371) is a central intracellular signaling pathway that transmits extracellular cues from cell surface receptors to the nucleus, controlling fundamental processes such as proliferation, differentiation, and survival. It is one of the most extensively studied MAPK cascades and is conserved from yeast to humans. The cascade is initiated by activation of a MAP3K (e.g., RAF), which phosphorylates and activates a MAP2K (MEK1/2), which in turn phosphorylates ERK1 (MAPK3) and ERK2 (MAPK1) on threonine and tyrosine residues. This sequential phosphorylation cascade amplifies signals and provides multiple points for regulation. Researchers study GO:0070371 because its dysregulation is implicated in cancer, developmental disorders, and other diseases, making it a prime target for therapeutic intervention. Understanding the specific roles of ERK1 versus ERK2 is critical, as they are not fully redundant.
ERK1 and ERK2 cascade At A Glance
| GO ID | GO:0070371 |
|---|---|
| GO term | ERK1 and ERK2 cascade |
| Ontology | biological_process |
| Synonym | ERK1/2 cascade; ERK1 and ERK2 signaling pathway; extracellular signal-regulated kinase 1/2 cascade; MAPK1 cascade; MAPK3 cascade |
| Major function | Transmits mitogenic and growth factor signals to regulate proliferation, differentiation, and development |
| Upstream activators | MAP4K, MAP3K (e.g., RAF), MAP2K (MEK1/2) |
| Downstream effectors | ERK1 (MAPK3), ERK2 (MAPK1); substrates include transcription factors and kinases |
| Key regulators | Scaffold proteins (e.g., KSR), phosphatases (DUSPs), feedback phosphorylation |
| Cellular outcomes | Cell proliferation, differentiation, development, survival, and migration |
What Is GO:0070371?
GO:0070371, the ERK1 and ERK2 cascade, is defined as a MAPK cascade that contains at least the ERK1 or ERK2 MAP kinases. It begins with the activation of a MAP3K, followed by the consecutive activation of a MAP2K and then ERK1 or ERK2. The cascade can also include an upstream MAP4K tier. In each tier, kinases phosphorylate and activate the kinase in the downstream tier. This cascade is activated by mitogens, growth factors, and G protein-coupled receptors, and it results in cellular responses such as cell proliferation, cell differentiation, and development.
Why Is ERK1 and ERK2 cascade Important in Cell Biology?
The ERK1 and ERK2 cascade is essential for normal development and tissue homeostasis, and its aberrant activation is a driving force in many human diseases, particularly cancer. Approximately one-third of all human cancers harbor mutations in the RAS-RAF-MEK-ERK pathway, making it one of the most validated oncogenic signaling cascades. Beyond cancer, ERK1/2 signaling contributes to cardiac hypertrophy, neurodevelopmental disorders, and immune responses. Because ERK1 and ERK2 have both overlapping and distinct functions, precise experimental models are needed to understand their individual contributions and to develop targeted therapies.
• Central pathway for cell proliferation and differentiation, often dysregulated in cancer.
• Mutations in upstream components (RAS, RAF) are common in human tumors.
• ERK1 and ERK2 have non-redundant roles in development and tissue homeostasis.
• Targeted inhibitors of MEK and ERK are in clinical trials for various cancers.
• The cascade is involved in learning and memory, and its dysfunction is linked to neurodevelopmental disorders.
• ERK1/2 signaling modulates immune cell activation and inflammation.
• Scaffold proteins and phosphatases provide specificity and negative feedback.
• Small molecule inhibitors targeting ERK2 D-recruitment site offer new therapeutic avenues.
• The pathway is a paradigm for understanding kinase cascade architecture and signal amplification.
• CRISPR-based models enable precise dissection of ERK1/2 functions in health and disease.
What Happens During ERK1 and ERK2 cascade?
Activation of upstream MAP3K
In simple terms: A signal from outside the cell turns on a first kinase called MAP3K.
The ERK1/2 cascade is typically initiated by ligand binding to receptor tyrosine kinases or G protein-coupled receptors, which leads to activation of the small GTPase RAS. RAS then recruits and activates the MAP3K RAF (ARAF, BRAF, or CRAF) at the plasma membrane. This step is a key point of regulation and is frequently mutated in cancers. MAP3K activation involves phosphorylation and conformational changes that relieve autoinhibition.
Activation of MAP2K (MEK1/2)
In simple terms: The first kinase activates a second kinase called MEK.
Activated RAF phosphorylates MEK1 and MEK2 (MAP2K1/2) on two serine residues in their activation loop. MEK1/2 are dual-specificity kinases that specifically phosphorylate ERK1/2 on both threonine and tyrosine residues. This tier provides amplification and integration of signals from multiple upstream inputs.
Activation of ERK1 and ERK2
In simple terms: MEK adds phosphate groups to ERK1 and ERK2, turning them on.
MEK1/2 phosphorylate ERK1 (MAPK3) and ERK2 (MAPK1) on the T-E-Y motif (Thr202/Tyr204 in ERK1; Thr185/Tyr187 in ERK2). This dual phosphorylation is required for full kinase activity and induces conformational changes that allow substrate binding. Activated ERK1/2 can phosphorylate both cytoplasmic and nuclear substrates.
Substrate phosphorylation and cellular responses
In simple terms: Active ERK proteins modify many other proteins to change cell behavior.
Activated ERK1/2 phosphorylate a wide range of substrates, including transcription factors (e.g., ELK1, c-FOS), kinases, and cytoskeletal proteins. This leads to diverse cellular outcomes such as proliferation, differentiation, migration, and survival. The specificity of substrate phosphorylation is influenced by scaffold proteins and subcellular localization.
Feedback regulation and termination
In simple terms: The pathway has built-in brakes to stop the signal.
ERK1/2 can phosphorylate upstream components such as RAF and MEK, providing negative feedback. Additionally, dual-specificity phosphatases (DUSPs) dephosphorylate ERK1/2 to terminate signaling. This tight regulation ensures transient and appropriate responses to extracellular cues.
Key Genes Involved in GO:0070371 ERK1 and ERK2 cascade
The following genes encode core components and regulators of the ERK1 and ERK2 cascade, many of which are frequent targets of CRISPR-based studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAPK3 (ERK1) | Terminal kinase of the cascade; phosphorylates substrates | Knockout models show specific roles in development and behavior |
| MAPK1 (ERK2) | Terminal kinase; essential for embryonic development | Knockout is embryonic lethal; point mutations used to study kinase activity |
| MAP2K1 (MEK1) | Dual-specificity kinase that activates ERK1/2 | Commonly mutated in cancers; target of allosteric inhibitors |
| MAP2K2 (MEK2) | Dual-specificity kinase that activates ERK1/2 | Redundant with MEK1 but has distinct functions |
| RAF1 (CRAF) | MAP3K that activates MEK1/2 | Mutations cause developmental disorders and cancer |
| BRAF | MAP3K that activates MEK1/2 | V600E mutation is a major oncogenic driver |
| ARAF | MAP3K that activates MEK1/2 | Less studied; potential role in specific cancers |
| RAS (HRAS, KRAS, NRAS) | Small GTPase that recruits RAF to membrane | Mutations are among the most common in cancer |
| KSR1 | Scaffold protein that facilitates RAF-MEK-ERK assembly | Modulates pathway specificity and intensity |
| DUSP1 | Phosphatase that dephosphorylates ERK1/2 | Negative regulator; often overexpressed in cancers |
| DUSP6 | Cytoplasmic phosphatase specific for ERK1/2 | Feedback regulator; biomarker for ERK activity |
| ELK1 | Transcription factor phosphorylated by ERK1/2 | Mediates immediate early gene expression |
| FOS | Transcription factor phosphorylated by ERK1/2 | Component of AP-1; regulates proliferation |
| MYC | Transcription factor stabilized by ERK1/2 signaling | Oncogene; links ERK to cell cycle |
| SPRY2 | Feedback inhibitor of RTK-RAS-ERK signaling | Tumor suppressor; regulates pathway duration |
| PTPN11 (SHP2) | Tyrosine phosphatase that promotes RAS activation | Mutations cause Noonan syndrome and leukemia |
| NF1 | GAP that inactivates RAS | Tumor suppressor; loss activates ERK cascade |
How Is ERK1 and ERK2 cascade Regulated?
The ERK1 and ERK2 cascade is tightly regulated at multiple levels. Upstream, receptor tyrosine kinases and G protein-coupled receptors control the intensity and duration of signaling. Scaffold proteins such as KSR1 and MP1 organize RAF, MEK, and ERK into complexes, enhancing specificity and efficiency. Negative feedback loops involve ERK-mediated phosphorylation of RAF, MEK, and upstream receptors, as well as induction of DUSP phosphatases that dephosphorylate ERK1/2. Additionally, cross-talk with other pathways (e.g., PI3K-AKT, mTOR) modulates ERK activity. Dysregulation of these regulatory mechanisms contributes to diseases such as cancer and developmental syndromes.
ERK1 and ERK2 cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BRAF | Melanoma, colorectal cancer | Knock-in of V600E mutation in cell lines; drug sensitivity assays |
| KRAS | Pancreatic, lung, colorectal cancer | Knockout and point mutation (G12D) models to study ERK activation |
| PTPN11 | Noonan syndrome, juvenile myelomonocytic leukemia | Knock-in of gain-of-function mutations; ERK activity readouts |
| MAP2K1 | Cardio-facio-cutaneous syndrome, melanoma | Point mutation knock-in; MEK inhibitor testing |
| MAPK1 (ERK2) | Developmental disorders, cancer | Knockout and kinase-dead knock-in to dissect specific functions |
Cancer
Constitutive activation of the ERK1/2 cascade due to mutations in RAS, RAF, or upstream receptors is a hallmark of many cancers, including melanoma, colorectal, and lung cancer. Targeting this pathway with MEK and ERK inhibitors has shown clinical benefit, but resistance mechanisms often emerge. Understanding ERK1/2-specific functions may guide combination therapies.
Neurodevelopmental disorders
Germline mutations in components of the ERK cascade, such as PTPN11, SOS1, RAF1, and MAP2K1, cause RASopathies, a group of developmental disorders including Noonan syndrome and cardio-facio-cutaneous syndrome. These mutations lead to hyperactive ERK signaling and affect craniofacial, cardiac, and cognitive development.
Cardiac hypertrophy and fibrosis
ERK1/2 signaling is activated in cardiac hypertrophy and heart failure. While acute ERK activation may be protective, chronic activation contributes to pathological remodeling. Targeting ERK1/2 in cardiac disease requires careful consideration of its homeostatic roles.
Inflammation and immune disorders
ERK1/2 signaling regulates immune cell activation, cytokine production, and inflammatory responses. Dysregulation is implicated in autoimmune diseases and chronic inflammation. Modulating ERK activity may offer therapeutic strategies for inflammatory conditions.
From ERK1 and ERK2 cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of ERK1 loss on proliferation? | ERK1 (MAPK3) knockout cell line |
| How does ERK2 kinase activity contribute to development? | ERK2 (MAPK1) point mutation (kinase-dead) knock-in |
| Does a cancer-associated MEK1 mutation activate ERK signaling? | MEK1 point mutation knock-in (e.g., Q56P) |
| How does ERK2 localization affect substrate specificity? | Tagged ERK2 knock-in (e.g., GFP) for imaging |
| What is the effect of ERK1/2 overexpression on drug resistance? | Inducible overexpression of ERK1 or ERK2 |
| Can CRISPR screening identify synthetic lethal partners of ERK inhibition? | Genome-wide CRISPR knockout library screening |
How to Study the ERK1 and ERK2 cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot for phospho-ERK1/2 | Activation status of ERK1/2 | Drug treatment response, pathway inhibition |
| In vitro kinase assay | Catalytic activity of ERK1/2 | Inhibitor screening, mutant characterization |
| RNA-seq | Transcriptional changes downstream of ERK | Identify gene expression signatures |
| Phosphoproteomics | Global phosphorylation events | Discover novel ERK substrates and networks |
| FRET biosensor imaging | Real-time ERK activity dynamics | Live-cell signaling kinetics |
| CRISPR knockout screening | Genes required for ERK-driven proliferation | Identify synthetic lethal targets |
| Immunofluorescence | Subcellular localization of ERK1/2 | Study nuclear translocation and tissue distribution |
| Co-immunoprecipitation | Protein-protein interactions | Map scaffold and substrate complexes |
Phospho-ERK immunoblotting and immunofluorescence
Detection of dual-phosphorylated ERK1/2 (Thr202/Tyr204) by Western blot or immunofluorescence is the standard method to assess pathway activation. It provides semi-quantitative readouts of ERK activity in cell lysates or fixed cells.
Kinase activity assays
In vitro kinase assays using recombinant ERK1/2 and substrate peptides (e.g., myelin basic protein) measure catalytic activity. These assays are useful for testing inhibitors and mutant enzymes.
Transcriptional reporters and RNA-seq
ERK1/2 activation drives expression of immediate early genes (e.g., FOS, EGR1). Luciferase reporters or RNA-seq can quantify pathway output and identify downstream transcriptional programs.
Proteomics and phosphoproteomics
Mass spectrometry-based phosphoproteomics identifies ERK1/2 substrates and signaling networks. This unbiased approach reveals context-specific phosphorylation events and crosstalk.
Live-cell imaging of ERK dynamics
Genetically encoded FRET biosensors or tagged ERK1/2 allow real-time monitoring of kinase activity and subcellular localization in living cells.
How CRISPR Can Be Used to Study GO:0070371 ERK1 and ERK2 cascade
Knockout
CRISPR-Cas9 knockout of MAPK3 (ERK1) or MAPK1 (ERK2) generates cell lines to study loss-of-function phenotypes. While ERK2 knockout is often lethal, ERK1 knockout cells are viable and reveal specific roles in development and behavior. Knockout of upstream regulators (e.g., RAF, MEK) helps dissect pathway dependencies.
Point Mutation
CRISPR-mediated point mutations (e.g., kinase-dead ERK2, constitutively active MEK1) allow precise interrogation of catalytic activity and substrate specificity without altering protein levels. These models are valuable for testing targeted inhibitors and understanding resistance mutations.
Knock-in
Knock-in of tagged ERK1/2 (e.g., GFP, HA) enables visualization and purification of endogenous proteins. Knock-in of disease-associated mutations (e.g., BRAF V600E, KRAS G12D) creates isogenic models to study oncogenic signaling and drug responses.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of ERK1/2 or upstream components can model pathway hyperactivation. Overexpression studies help identify dose-dependent effects and potential oncogenic addiction.
How EDITGENE Supports ERK1 and ERK2 cascade Research
Researchers studying ERK1 and ERK2 cascade-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or drug response. Generating precise genetic models is essential to move from correlation to causation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for ERK1 and ERK2 cascade research.
Frequently Asked Questions About ERK1 and ERK2 cascade
What is the ERK1 and ERK2 cascade?
The ERK1 and ERK2 cascade (GO:0070371) is a MAPK signaling pathway that transmits signals from cell surface receptors to the nucleus, regulating proliferation, differentiation, and development.
What genes are involved in the ERK1 and ERK2 cascade?
Key genes include MAPK3 (ERK1), MAPK1 (ERK2), MAP2K1 (MEK1), MAP2K2 (MEK2), RAF1, BRAF, and RAS family genes.
What is the difference between ERK1 and ERK2?
ERK1 (MAPK3) and ERK2 (MAPK1) are highly similar but not fully redundant; ERK2 knockout is embryonic lethal in mice, while ERK1 knockout mice are viable, indicating distinct functions.
How is the ERK1/2 cascade activated?
It is activated by growth factors, mitogens, and G protein-coupled receptors through sequential phosphorylation of MAP3K, MAP2K, and ERK1/2.
What diseases are associated with ERK1/2 signaling?
Dysregulated ERK1/2 signaling is implicated in many cancers, RASopathies (developmental disorders), cardiac hypertrophy, and inflammatory diseases.
How can I study ERK1/2 activity in cells?
Common methods include Western blotting for phospho-ERK1/2, kinase assays, luciferase reporters, and live-cell imaging with FRET biosensors.
What are ERK1/2 inhibitors?
Small molecule inhibitors targeting MEK or ERK are used in cancer therapy; examples include trametinib (MEK inhibitor) and ERK inhibitors in clinical trials.
Can CRISPR be used to study ERK1/2 function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of ERK1/2-specific roles in health and disease.
What is the role of ERK1/2 in cancer?
Constitutive ERK1/2 activation drives uncontrolled proliferation and survival in many cancers, often due to mutations in RAS or RAF.
How does EDITGENE support ERK1/2 research?
EDITGENE provides custom CRISPR cell models (knockout, point mutation, knock-in, overexpression) and library screening services to study ERK1/2 cascade genes.
Conclusion
The ERK1 and ERK2 cascade (GO:0070371) is a fundamental signaling pathway that controls cell fate decisions and is frequently dysregulated in human disease. Understanding the specific contributions of ERK1 and ERK2, as well as upstream regulators and feedback mechanisms, requires precise genetic models. CRISPR-based approaches offer unprecedented opportunities to dissect this pathway and identify new therapeutic targets. EDITGENE's comprehensive services empower researchers to generate custom models and accelerate discoveries in ERK1/2 biology.
References
- 1. Guo YJ et al.. 2020. ERK/MAPK signalling pathway and tumorigenesis.. Exp Ther Med 19(3):1997-2007 PMID: 32104259
- 2. Roskoski R Jr. 2012. ERK1/2 MAP kinases: structure, function, and regulation.. Pharmacol Res 66(2):105-43 PMID: 22569528
- 3. Buscà R et al.. 2016. ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?. Front Cell Dev Biol 4:53 PMID: 27376062
- 4. Sah VK et al.. 2025. Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation.. J Enzyme Inhib Med Chem 40(1):2555510 PMID: 40928301
- 5. Schanbacher C et al.. 2026. Targeting pathological ERK1/2 signaling in cancer and beyond.. Trends Mol Med 32(3):231-255 PMID: 40914707
- 8. Sammons RM et al.. 2023. Identification and biochemical characterization of small molecule inhibitors of ERK2 that target the D-recruitment site.. Methods Enzymol 690:445-499 PMID: 37858538
